|
Scientists develop powerful method for finding therapeutic antibodies
R & D Magazine Scientists at The Scripps Research Institute (TSRI) have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world’s … New antibody technology discovers drugs rapidlyU-T San Diego |
Arsanis Nominates Preclinical Candidate for Staphylococcus aureus ProgramPipelineReview.com (press release)VIENNA, Austria I May 23, 2013 I Arsanis Biosciences GmbH, a biotechnology company developing anti-infective human monoclonal antibodies, achieve…
|
Scientists develop powerful new method for finding therapeutic antibodies
EurekAlert (press release) LA JOLLA, CA – May 23, 2013 – Scientists at The Scripps Research Institute (TSRI) have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are … New antibody technology discovers drugs rapidlyU-T San Diego |
|
New antibody technology discovers drugs rapidly
U-T San Diego LA JOLLA — Monoclonal antibodies, drugs that already rank among the world’s top biotech products, could become far more versatile with technology developed by scientists from The Ssripps Research Institute. The technology rapidly finds antibodies that … |
|
Scientists develop powerful new method for finding therapeutic antibodies
Phys.Org Scientists at The Scripps Research Institute (TSRI) have devised a powerful new technique for finding antibodies that have a desired biological effect. Antibodies, which can bind to billions of distinct targets, are already used in many of the world’s … New antibody technology discovers drugs rapidlyU-T San Diego |
Scotsman |
Non-Hodgkin lymphoma survival doubles since early 1970s
Medical Xpress These vast improvements are largely thanks to better treatments – particularly the drug rituximab, which Cancer Research UK scientists laid the groundwork for with their early work into the immune system – and earlier diagnosis linked to improved … New treatments see blood cancer survival rates upScotsman |
21-day R-CHOP regimen remains standard in diffuse B-cell lymphomasHealioA 14-day regimen of rituximab plus CHOP failed to demonstrate improvement compared with the standard 21-day regimen in a cohort of patients with previously B-cell lymphomas, accord…
|
It’s all in what you say and how you say it
Lexology (registration) Subsequently, scientists found that rituximab could be used to treat another blood cancer, i.e., chronic lymphocytic leukemia (CLL), and Biogen filed a patent application based on this finding. This patent issued as US Patent No. 7,682,612, with claim … |
Cancer Research UK (press release) |
Non-Hodgkin lymphoma survival doubles since early 1970s
Cancer Research UK (press release) These vast improvements are largely thanks to better treatments – particularly the drug rituximab, which Cancer Research UK scientists laid the groundwork for with their early work into the immune system – and earlier diagnosis linked to improved … New treatments see blood cancer survival rates upScotsman |
Medical DailyEnzyme-activating antibodies revealed as marker for most severe form of …Science Daily (press release)In the study, the antibodies were present — in 18 percent of 44 fluid samples from one research collection and in 12 percent of anothe…